Navigation Links
Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
Date:4/18/2013

LONDON, April 18, 2013 /PRNewswire/ -- Replikins Ltd will reveal details on the availability of two completely synthetic vaccine candidates, both with long-term prevention goals and acute short-term blocking capacity.  One of these vaccines targets H7N9 alone, the other for H7N9 plus the other common influenza strains. The company is exploring partnerships with established healthcare and pharmaceutical companies to aggressively commercialize the technology. 

Because Replikins is leveraging proprietary software techniques to isolate targeted regions in the virus, combined with recent advances in manufacturing synthetic peptides, the company and its partners are able to provide rapid turnaround of vaccine candidates based on early data emerging from disease outbreaks.  This approach stands in marked contrast to projections by other companies of delays of seven months or longer before vaccines can be made available, and makes it possible to consider effective public health responses to disease outbreaks while they are still at an early stage.

Replikins will provide details of the technology and is seeking partnerships at the BIO International Convention April 22nd-25th at its booth #3456, McCormick Place, Chicago.

The technique used to create Replikins' new synthetic vaccine candidates is similar to those the company used in manufacturing a successful Replikins H5N1 "bird flu" vaccine in chickens in a paper published in 2009.  That vaccine was produced in 7 days, shipped freeze-dried, and administered via the respiratory tract.  Significantly, in addition to stopping the virus in the chickens, excretion of the virus was completely prevented, thus potentially interfering with the build-up of virus reservoirs which encourage mutations.

Contact: Dr. Samuel Bogoch , 646-320-5910, Email

References:

1.  Nature Precedings.  Bogoch et al, doi:10.1038/npre.2012.6952.1

(see also seven additional  Nature Precedings Publications, Bogoch 2011-2012. http://precedings.nature.com/users/549471c7b195af1864d2f1b1996f60642.

2.  www.replikins.com

3. Dr. Sanjay Gupta of CNN Reports on Replikins (www.replikins.com)

4. Jackwood et al. Avian Diseases 53(4): 613‐617, 2009

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New White Paper Details What Compounding Pharmacies Must Know to Prepare for FDA Inspections
2. CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results
3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
4. Generex Announces Details of Investor Conference Call
5. White Paper Details Five Things to Consider Before Buying Spiral Bevel Gear Drives
6. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
7. New Report Details NCPA Efforts to Drive Greater Medication Adherence
8. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
9. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
10. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
11. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
Breaking Medicine News(10 mins):